1. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin, Giovanna Piaggio, Francesca Bertolotti, Raffaella Grasso, Simona Zupo, Anna Maria Raiola, Marco Gobbi, Francesco Frassoni, and Andrea Bacigalupo
Blood
Volume 109(11):
June 1, 2007
©2007 by American Society of Hematology

2. Actuarial survival and cumulative incidence of leukemia relapse in patients with acute leukemia undergoing an allogeneic stem cell transplantation.
Actuarial survival and cumulative incidence of leukemia relapse in patients with acute leukemia undergoing an allogeneic stem cell transplantation. The patients are divided into 3 groups: MRD+DLI+, n = 17 (patients with positive minimal residual disease, receiving donor lymphocyte infusion); MRD–, n = 44 (patients with negative MRD); and MRD+DLI–, n = 19 (patients with positive MRD who did not receive DLI). The actuarial survival of MRD+DLI+ patients is comparable to the actuarial survival of MRD– patients, due to a low risk of relapse in both groups. Survival of MRD+DLI– patients is significantly worse, due to a higher risk of leukemia relapse in this group (P < .001).
Alida Dominietto et al. Blood 2007;109:
©2007 by American Society of Hematology